Drug Trial Radar · NCT06433219
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
63
Actual
Start
Oct 30, 2024
Primary completion
Aug 11, 2026
Study completion Aug 11, 2026
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- May 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the effect and safety of treatment with tuvusertib combined with either niraparib or lartesertib in participants with epithelial ovarian cancer and to assess any differences between tuvusertib monotherapy and combination therapy. The participants will previously have progressed while treated with a poly ADP ribose polymerase (PARP) inhibitor. The primary objectives of this study are to assess the effect of the treatment in terms of overall response, i.e. whether the tumor disappears, shrinks, remains unchanged, or gets worse and safety in terms of adverse events.
Conditions
- Ovarian Cancer
Interventions
Tuvusertib (M1774)Drug
Tuvusertib will be administered orally.
NiraparibDrug
Niraparib will be administered orally. If selected from Part A, Niraparib will be administered orally in combination with Tuvusertib.
Lartesertib (M4076)Drug
Lartesertib will be administered orally. If selected from Part A, Lartesertib will be administered orally in combination with Tuvusertib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A and Part B: Confirmed Objective Response (OR) According to RECIST v1.1 as Assessed by InvestigatorTime frame: Time from randomization to final assessment or until progressive disease, death, discontinuation criteria, approximately up to 3.5 years
- Part A and Part B: Number of Participants With Treatment-Emergent Adverse Events (TEAE), Serious TEAEs and Related TEAEsTime frame: Time from randomization to final assessment at end of safety follow-up visit, approximately up to 3.5 years
Locations
84 sites in 13 countries. Site status is shown where the registry gives one.
University of Arkansas for Medical Sciences
Little Rock, Arkansas
University of California San Francisco - UCSF Medical Center
San Francisco, California
Centricity Research Cancer Center - DBA CRRI John B. Amos Cancer Center Research
Columbus, Georgia
University of Chicago Comprehensive Cancer Center at Silver Cross - Carolyn J. Czerkies Pavilion
Chicago, Illinois
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan
Memorial Sloan Kettering Cancer Center
New York, New York
Icahn School of Medicine at Mount Sinai PRIME - Mount Sinai - PRIME
New York, New York
Next Oncology - Virginia
Fairfax, Virginia
Virginia Cancer Specialists, PC
Fairfax, Virginia
Chris O'Brien Lifehouse
Camperdown, Australia
St George Private Hospital
Kogarah, Australia
Liverpool Hospital - PARENT
Liverpool, Australia
Cliniques Universitaires Saint-Luc - STL
Brussels, Belgium
UZ Leuven
Leuven, Belgium
Ålborg Universitets Hospital - PARENT
Aalborg, Denmark
Rigshospitalet
Copenhagen, Denmark
Sjaellands Universitetshospital - other
Odense, Denmark
ICO - Site Paul Papin - service d'oncologie medicale
Angers, France
Centre Francois Baclesse - Service d'Oncologie Medicale
Caen, France
Centre Oscar Lambret - service de cancerologie gynecologique
Lille, France
Centre Leon Berard - Service d'Oncologie Medicale
Lyon, France
Groupe Hospitalier Diaconesses - Hôpital De La Croix Saint Simon - service d'oncologie medicale
Paris, France
Hopital Tenon - service d'oncologie medicale
Paris, France
Hôpital Cochin - Hematologie et Oncologie Médicale
Paris, France
Hôpital Européen Georges Pompidou - Hématologie Oncologie
Paris, France
Hôpital Saint Joseph - Paris - Service d'Oncologie-Cancerologie
Paris, France
Centre Hospitalier Lyon Sud - service d'oncologie medicale
Pierre-Bénite, France
Centre de Radiotherapie Clinique Sainte Anne - 300207251
Strasbourg, France
Institut de Cancérologie de Strasbourg Europe - ICANS - Service d'oncologie médicale
Strasbourg, France
Institut Gustave Roussy - Oncologie Médicale
Villejuif, France
Charité - Campus Virchow-Klinikum - Klinik fuer Gynaekologie
Berlin, Germany
Universitaetsklinikum Bonn AoeR - Frauenklinik
Bonn, Germany
Universitaetsklinikum Carl Gustav Carus TU Dresden - Klinik u. Poliklinik f. Frauenheilkunde
Dresden, Germany
Kliniken Essen-Mitte - Gynaekologie und Gynaekologische Onkologie
Essen, Germany
Universitaetsklinikum Leipzig AoeR - Klinik und Poliklinik fuer Frauenheilkunde
Leipzig, Germany
Universitaetsklinikum Muenster - Parent
Münster, Germany
Universitätsklinikum Münster - Gynecology
Münster, Germany
Caritas-Krankenhaus St. Josef - Klinik fuer Chirurgie
Regensburg, Germany
Universitaetsklinikum Tuebingen - Parent
Tübingen, Germany
Rambam Medical Center
Haifa, Israel
Showing 40 of 84 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.